Kyowa Kirin forms global collaborative with advocacy groups to address unmet needs in cutaneous T-cell lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kyowa Kirin published a patient-focused global consensus statement that highlights 12 recommendations for healthcare authorities, policymakers, hospitals, and clinicians to drive positive change for the global cutaneous T-cell lymphoma patient community.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In this week's episode of The Cancer Letter Podcast, editor and publisher Paul Goldberg, and associate editor Jacquelyn Cobb revisit two of last week’s most-read stories: the growing recognition that early-onset colorectal cancer requires a new diagnostic mindset, and the life and legacy of Maura Gillison, the scientist whose discovery that most head and neck cancers are driven by HPV transformed the field. 
Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase inhibitor, plus a two-year venetoclax and rituximab regimen versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001), according to the results of the phase III BRUIN CLL-322 trial. The study met its primary endpoint of independent review committee-assessed progression-free survival.
The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login